Terms: = Cervical cancer AND SETBP1, Q9UEF3, Q6P6C3, A6H8W5, Q9Y6X0, 26040, SEB, KIAA0437, ENSG00000152217
6 results:
1. Simultaneous integrated or sequential boost to clinically involved lymph nodes in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.
Kahvecioglu A; Gurlek E; Yedekci FY; Sari SY; Gultekin M; Yildiz F
Gynecol Oncol; 2023 Sep; 176():10-15. PubMed ID: 37413947
[TBL] [Abstract] [Full Text] [Related]
2. Depressed type 1 cytokine synthesis by superantigen-activated CD4+ T cells of women with human papillomavirus-related high-grade squamous intraepithelial lesions.
Lee BN; Follen M; Shen DY; Malpica A; Adler-Storthz K; Shearer WT; Reuben JM
Clin Diagn Lab Immunol; 2004 Mar; 11(2):239-44. PubMed ID: 15013969
[TBL] [Abstract] [Full Text] [Related]
3. Why phase II trials in cervical chemoprevention are negative: what have we learned?
Follen M; Vlastos AT; Meyskens FL; Atkinson EN; Schottenfeld D
Cancer Causes Control; 2002 Nov; 13(9):855-73. PubMed ID: 12462551
[TBL] [Abstract] [Full Text] [Related]
4. DNA image cytometric measurement as a surrogate end point biomarker in a phase I trial of alpha-difluoromethylornithine for cervical intraepithelial neoplasia.
Boiko IV; Mitchell MF; Pandey DK; White RA; Hu W; Malpica A; Nishioka K; Boone CW; Atkinson EN; Hittelman WN
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):849-55. PubMed ID: 9332769
[TBL] [Abstract] [Full Text] [Related]
5. In vivo fluorescence spectroscopy: potential for non-invasive, automated diagnosis of cervical intraepithelial neoplasia and use as a surrogate endpoint biomarker.
Richards-Kortum R; Mitchell MF; Ramanujam N; Mahadevan A; Thomsen S
J Cell Biochem Suppl; 1994; 19():111-9. PubMed ID: 7823582
[TBL] [Abstract] [Full Text] [Related]
6. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention.
Boone CW; Kelloff GJ
J Cell Biochem Suppl; 1993; 17F():37-48. PubMed ID: 8412208
[TBL] [Abstract] [Full Text] [Related]
